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Abstract 
 
 
 
There are a number of challenges in the economic evaluation of medical devices 
(MDs). They are typically less regulated than pharmaceuticals and the clinical 
evidence requirements for market authorization is generally lower. There are also 
specific characteristics of MDs, such as the device-user interaction (learning curve), 
the incremental nature of innovation, the dynamic nature of pricing and the broader 
organizational impact. Therefore, a number of initiatives need to be taken in order to 
facilitate the economic evaluation of MDs. First, the regulatory processes for MDs 
need to be strengthened and more closely aligned to the needs of economic 
evaluation. Secondly, the methods of economic evaluation need to be enhanced, by 
improving the analysis of the available clinical data, by establishing high-quality 
clinical registries and betWHUUHFRJQL]LQJ0'V¶specific characteristics. Thirdly, the 
market entry and diffusion of MDs needs to be better managed, by understanding the 
key influences on MD diffusion and by linking diffusion with cost-effectiveness 
evidence through the use of performance-based risk-sharing arrangements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
 
Medical devices (MDs) represent an important group of health technologies. In 2011 
it was estimated that there were more than 200,000 MDs on the European market 
(Fraser et al, 2011). However, MDs represent a very heterogeneous family of 
technologies, consisting of both diagnostic and therapeutic devices, and ranging from 
µORZULVN¶GHYLFHVVXFKDVVFDOSHOVWRµKLJKULVN¶GHYLFHVVXFKDVFDUGLDFLPSODQWDEOH
electrical devices. While some devices only require very simplified assessment, 
others need to be assessed through a full evaluation of safety, efficacy, effectiveness 
and cost-effectiveness. 
 
Many of the early applications of economic evaluation in health care were of the use 
of medical procedures involving devices, such as kidney dialysis (Klarman et al 
1968), or of expensive diagnostic devices such computed tomography (CT) scanners 
(Office of Technology Assessment, 1978). However, the more recent literature in 
economic evaluation has focused largely on pharmaceuticals, reflecting the growth of 
formal requirements for new drugs to demonstrate cost-effectiveness in order to be 
reimbursed in many jurisdictions (Drummond, 2013). For example, in 2016 the 
National Institute of Health and Care Excellence (NICE) in the UK, one of the most 
active heath technology assessment organizations worldwide, published 50 
technology appraisals of pharmaceuticals, but only 3 appraisals of medical devices 
and 6 of diagnostic technologies (www.nice.org.uk). 
 
This relative lack of economic evaluations of MDs as compared with pharmaceuticals 
has led some authors to question whether devices have any special characteristics 
that inhibit their assessment and whether, over time, the methods guidelines for 
economic evaluation have become more suited to the assessment of 
pharmaceuticals (Tarricone et al, 2017a). The challenges in conducting economic 
evaluation of medical devices are related to two major issues. The first lies in the 
policy domain and regards current regulatory requirements, which are typically less 
stringent than for pharmaceuticals. As a consequence, evidence produced by 
manufacturers applying for marketing approval is often not sufficient for subsequent 
economic evaluation analysis. The second issue is purely methodological, and 
reflects the ongoing debate on whether devices have distinctive features that require 
different or modified methods for economic evaluation to be applied properly. This 
article discusses the challenges in conducting economic evaluations of MDs, from 
both policy and methodological viewpoint, and provides some suggestions on how 
they might be addressed. 
 
 
1.1 Regulatory requirements for MDs 
 
One critical issue relates to the fact the regulatory requirements for devices are 
typically less stringent than those for pharmaceuticals. In order to obtain approval to 
market, pharmaceuticals normally require two adequately controlled clinical trials. In 
contrast, the level of clinical evidence required for the marketing of MDs varies by the 
risk classification of the device. The risk classifications differ slightly by jurisdiction, 
but generally divide devices into 3 or 4 groups (Tarricone et al, 2014).  
 
Low risk devices, such as crutches and scalpels, are generally exempt from 
premarket approval, although they need to be registered and are subject to labeling 
regulations. In the European Union this means obtaining a CE (Conformité 
Europeéne) mark. Devices of medium risk, such as catheters and infusion pumps, do 
require premarket approval and often the manufacturer is required to submit a 
dossier of relevant clinical and non-clinical data. The data required usually depends 
on the level of perceived risk. For example, in some jurisdictions (eg the European 
Union), RUWKRSDHGLFLPSODQWVDUHFODVVLILHGDVµPHGLXPULVN¶EXWPDQXIDFWXUHUVZRXOG
be expected to provide some clinical data and also establish a registry so that the 
performance of the device could be monitored after it enters the market. 
 
Finally, high risk devices such as coronary stents, cardiac pacemakers and 
implantable defibrillators always require clinical data, although the nature of that data 
may differ by jurisdiction. In the US the Food and Drug Administration often requires 
a randomized controlled trial, similar to its requirement for pharmaceuticals, whereas 
in the EU it may be possible to obtain market approval by conducting an 
observational study (eg a clinical registry). This was the case for transcatheter aortic 
valve implantation (TAVI), where an RCT was conducted in the US, but an 
observational study was established in Europe (Tarricone and Drummond, 2011).  
 
Another feature of the regulation of MDs that differs from pharmaceuticals is that 
PDQXIDFWXUHUVFDQFODLPWKDWWKHLUGHYLFHLVµVXEVWDQWLDOO\HTXLYDOHQW¶WRDQRWKHU
marketed device for which clinical data are available. An example of this approach is 
the 510(k) process in the US (Sorenson and Drummond, 2014). This can greatly 
asVLVWVRPHPDQXIDFWXUHUVNQRZQDVµIDVWIROORZHUV¶EXWKDVWKHHIIHFWRIQRW
DOORZLQJµGDWDH[FOXVLYLW\¶WRWKHPDQXIDFWXUer of the original device, as is the case for 
pharmaceuticals. This can have the effect of reducing the incentives for 
manufacturers to invest in clinical research, if that research is not mandatory, since 
the data generated can also be used by their competitors. 
 
A major impact of the current processes for regulating devices is that there is a 
relative lack of clinical data at the time of product launch, although there remains the 
possibility of further clinical data collection while the device is in regular clinical use. 
This limits the possibilities for conducting economic evaluations early in the life cycle 
of the technology, especially at the time of product launch. Therefore, it has been 
argued that a different strategy may have to be followed for conducting economic 
evaluations of MDs, focusing more on assessments in the post-marketing phase 
(Tarricone et al, 2014).  However, conducting economic evaluations in real life 
settings poses methodological challenges in the analysis of observational data, 
which are subject to numerous biases. Furthermore, evidence synthesis becomes 
even more demanding when data needs to be synthesised across studies with 
different designs (Schnell-Inderst et al, 2017).  
 
 
1.2 Special characteristics of MDs 
 
It has been suggested that there are a number of special characteristics of MDs that 
pose additional challenges for their clinical and economic evaluation (Drummond et 
al, 2009). These include the fact that (i) there is often an interaction between the 
device and the user (eg a surgeon), meaning that the performance of the device may 
change over time (the so-FDOOHGµOHDUQLQJFXUYH¶, as a given user gains more 
experience  (ii) MDs are characterized by incremental innovation, where small 
improvements are made, either through modifications to an existing device or the 
introduction of new products (iii) the introduction of MDs can have a substantial 
organizational impact, by requiring training or investments in infrastructure and (iv the 
pricing of MDs is more dynamic than that for other health technologies, owing to the 
extensive use of competitive tendering in the procurement process. In particular, the 
learning curve may have substantial effects on both effectiveness and costs. A more 
experienced surgeon may obtain better clinical results than one performing a 
procedure for the first time. In turn, better clinical outcomes might reduce the total 
length of hospital stay, or the need for subsequent procedures, which could also 
have an impact on costs. Also, a more skilled surgeon may perform the initial 
procedure more quickly, which could reduce the amount of expensive operating 
theatre time required. 
 
There is some evidence to support these assertions. For example, the learning curve 
for MDs has been observed in several clinical trials. In the CLASICC Trial of 
laparoscopic-assisted colorectal surgery, the proportion of patients requiring 
µUHYLVLRQV¶Le repeat procedures) fell from 38% in the first year of the trial, to 16% in 
year six (Guillou et al, 2005). Similarly, in a clinical trial of spinal chord stimulation 
versus percutaneous myocardial laser revascularization for patients with angina, 
improvements in the outcome from use of the new procedure caused the estimated 
incremental cost-effectiveness ratio (ICER) to fall from £230,000 per quality-adjusted 
life-year (QALY) in 2000/1 to £18,000 per QALY in 2002/3 (Dyer et al, 2008). 
Learning curve effects have also been observed in the use of procedures in regular 
clinical practice. Using individual patient level data obtained from a hospital 
discharges database in Germany over the period 2006-13, Varabyova et al (2017) 
found that, over time, both the in-hospital mortality and length of stay became lower 
for patients undergoing endovascular aneurism repair (EVAR), implying that the 
impact of the learning curve on cost-effectiveness can be more substantial than that 
on effectiveness alone. Conversely, there was no similar learning effect for a related 
procedure, fenestrated endovascular repair (fEVAR), possibly because much of the 
µOHDUQLQJ¶IURPSHUIRUPLQJ(9$5SURFHGXUHVZDVWUDQVIHUDEOHWRI(9$5 
 
The issue of incremental innovation was raised in a clinical and economic evaluation 
of stapled hemorrhoidectomy conducted for the National Institute for Health and Care 
Excellence (NICE) in the UK (Burch et al, 2008). The researchers found that, 
although clinical trials comparing staple guns versus conventional surgery did exist, 
most of the trials were conducted using older versions of the gun, which had 
undergone several modifications. However, it could be argued that, as long as the 
modifications represented improYHPHQWVWRWKHGHYLFH¶VSHUIRUPDQFHDQGWKH
learning curve in using the new version of the gun was not substantial, it would be 
conservative to use the older clinical evidence in the economic evaluation. 
Nevertheless, in some cases using clinical data from an older version of a technology 
could have a substantial impact on the results of the economic evaluation. 
 
Organizational impacts have been observed, but not examined quantitatively. For 
example, Tarricone and Drummond (2011) discussed the fact that adoption of 
transcatheter aortic valve implantation (TAVI) in a given hospital would normally 
involve investments in infrastructure and training. Because of the complexity and 
high risk of patients, TAVI would ideally need to be performed in a hybrid 
setting with equipment and facilities including both operating rooms and 
catheterisation laboratories (cathlabs). Alternatively, it could be delivered either in 
operating rooms with adequate visualisation equipment or in sterile cathlabs. This 
remains a challenge WRGD\VLQFHµSXUH¶K\EULGRSHUDWLQJ rooms or appropriately 
equipped operating rooms and cathlabs are the norm only in the most advanced 
hospitals and would need to be developed further if TAVI were to be more widely 
diffused. Logistics and multi-disciplinary team approaches also represent an 
organizational issue for many hospitals and must be assessed against investment 
costs in training and equipment. Moreover, a minimum number of cases needs to be 
planned in order to secure the return on the investment and, more importantly, the 
sufficient level of performance.  
 
The impact of price changes on the cost-effectiveness of MDs was illustrated in the 
technology appraisals conducted on drug-eluting stents (DES) by the National 
Institute for Health and Care Excellence (NICE) in the United Kingdom (UK). In the 
initial appraisal, conducted in 2004, NICE found that DES were cost-effective 
(according to its threshold of £20,000 per QALY gained) for patients with a high risk 
of restenosis. However, when NICE reappraised DES in 2008, the price of bare 
metal stents (the alternative technology) had fallen substantially, pushing the 
estimated incremental cost-effectiveness ratio (ICER) DERYH1,&(¶VWKUHVKROG
(Drummond et al, 2009). 
 
Therefore, taken together, these special characteristics can influence the planning 
and analysis of cost-effectiveness studies. For example, the potential existence of a 
learning curve suggests that the cost-effectiveness of MDs should be studied over a 
period of time, as the results when the device is first introduced may be misleading. 
The potential existence of incremental innovation is a challenge for the clinical 
component of the assessment, as (in principle) separate clinical studies may need to 
be conducted for each version of the device. In addition, if the changes in the 
benefits to patients from using the new version of a device are small, these may not 
be reflected in changes in the generic instruments used for estimating the quality-
adjusted life-years (QALYs) gained. Therefore, analysts wanting to estimate the 
value of these changes may need to estimate LQGLYLGXDOV¶ZLOOLQJQHVV-to-pay or 
conduct a discrete choice experiment (Wilkinson and Drummond, 2015). (See 
Section 2.2.3 below.) 
 
The potential for organizational impacts of devices suggests that the perspective for 
costing needs to be broad, covering a wide range of hospital departments and 
possibly also primary care, if use of the device changes the pattern of care. In 
addition, implementation costs, such as training and the provision of additional 
support services, may also need to be considered. Finally, the possibility of dynamic 
pricing suggests that a sensitivity analysis should be performed on both the 
acquisition cost of the new device and the one that it is replacing. 
 
A more fundamental point relating to the special characteristics of MDs is that, as 
FRPSDUHGZLWKGUXJVWKHµUHDOZRUOG¶FRVW-effectiveness may differ substantially from 
that observed within the context of controlled clinical trials. This suggests that the 
conduct of economic evaluations might be better focused on the post-marketing 
phase, rather than pre-marketing phase, as in the case of pharmaceuticals. This 
issue is discussed further in Section 3 below.   
 
On the other hand, it has been argued that, to the extent that these differences exist 
between MDs and other technologies (in particular pharmaceuticals), the differences 
are only a matter of degree (Taylor and Iglesias, 2009). For example, over time 
physicians may learn how to prescribe a drug more precisely in order to obtain the 
optimum balance between efficacy and adverse events, new modes of administration 
for a given drug (eg oral instead of intravenous infusion) might be viewed as 
incremental innovations, or alternatively may lead to shifts in care from an inpatient 
to an outpatient setting with the associated changes in infrastructure. Furthermore, 
tendering or price competition applies to pharmaceuticals in some jurisdictions (eg 
US managed care) and there are tendering processes for vaccines in many 
jurisdictions. Nevertheless, the special characteristics mentioned above are likely to 
have a greater impact in the economic evaluation of devices than other health 
technologies, so they need to be considered. 
 
Another important characteristic is that many MDs, such as CT scanners, are 
diagnostic. The economic evaluation of these technologies presents three specific 
challenges. First, the major benefit arising from diagnostic technologies is their ability 
to improve treatment choices and hence final health outcomes. Therefore, an 
accurate diagnostic test is only as good as the treatment that follows it. This means 
that the economic evaluation of a diagnostic technology usually encompasses the 
evaluation of the associated treatment technologies, with all the inherent challenges 
of conducting the required clinical evaluations. 
 
Secondly, although the major economic benefit of diagnostic technologies results 
from the improvement in treatment outcomes, there may be value in just knowing the 
accurate diagnosis, both to the patient and the physician, even if this does not affect 
the immediate treatment choices. In some cases there may be value from the 
reassurance offered by a diagnostic test. Although these aspects of value could, in 
principle, be detected by the standard measures of outcome used in economic 
evaluations, such as the quality-adjusted life-year (QALY), on occasions these 
measures may lack the adequate sensitivity. Therefore, it might be necessary to use 
alternative measures of value, such as willingness-to-pay (Lin et al, 2013).  
 
Thirdly, there are indivisibilities in the use of large diagnostic MDs such as scanners. 
This means that, not only is it necessary to show that individual indications for use of 
the scanner, it is also necessary that the totality of the workload required to occupy 
the scanner results in a cost-effective use of resources. If there were only a few 
potentially cost-effective indications for the scanner, this would not justify the large 
capital expenditure. 
 
 
 
2. Initiatives to improve the economic evaluation of MDs 
 
2.1 Improving the clinical evidence base for MDs 
 
It was mentioned above that the paucity of clinical data, particularly prior to market 
entry of MDs, can limit the possibilities for economic evaluation and health 
technology assessment (HTA). Drummond et al (2016) discussed several options for 
resolving this problem. First, the requirements for conducting clinical studies in the 
pre-marketing phase could be strengthened by, for example, insisting on randomized 
controlled trials for all high-risk devices and some medium risk devices (eg 
orthopaedic implants). However, this would impose greater costs on manufacturers 
and delay access to new treatments (Shuren and Califf, 2016). However, these 
considerations need to be balanced by the fact that potentially unsafe or ineffective 
devices could be allowed on the market before adequate evidence is available (Food 
and Drug Administration, 2016).  
 
Another initiative would be to tighten the conditions under which a manufacturer can 
FODLPµVXEVWDQWLDOHTXLYDOHQFH¶WRDSre-existing device already on the market. This 
would go some way towards restoring the incentives for research that follow from 
maintaining data exclusivity. However, this could result in a waste of resources in 
conducting clinical studies that are not necHVVDU\$OVRVLQFHVRPHRIWKHµIDVW-
IROORZHUV¶DUHVPDOODQGPHGLXP-size enterprises, which might find the cost of 
conducting clinical studies a challenge, this policy would have the impact of reducing 
price competition, thereby denying the health care system of some efficiency gains. 
 
The third possibility would be to strengthen the arrangements for post-market 
research. One argument for this policy would be that, due to some of the special 
characteristics of MDs mentioned above, requiring more RCTs in the pre-market 
phase might not be very helpful. For example, if there is likely to be a substantial 
learning curve for the device in question, it would be preferable to base the economic 
evaluation on clinical effectiveness in regular use, rather than under the experimental 
conditions of an RCT. Also, it there are likely to be several modifications of the 
product in the early years of its use, the clinical data gathered in the trial may quickly 
become outdated. 
 
However, there are several disadvantages of delaying economic evaluation to the 
post-market phase. It is often more difficult, and costly, to remove a treatment or 
technology from the market once it has entered the health care system. Also, once 
the technology is routinely available it is more difficult, if not impossible, to conduct a 
randomized clinical trial, since this implies that 50% of patients participating in the 
trial would not receive the new treatment. However, ways might be found to 
overcome this by, for example, randomizing one group of patients to delayed 
treatment rather than no treatment. 
 
These difficulties mean that the clinical studies conducted post-launch are likely to be 
observational studies, which often suffer from selection bias and are therefore more 
likely to produce a biased assessment of relative treatment effect (Grieve et al, 
2016). Of course statistical approaches are available to minimize the impact of 
selection bias, but it cannot be eliminated. However, in some situations only 
observational studies may be possible. 
 
These considerations suggest that any strategy for conducting economic evaluation 
in the post-marketing phase needs to be part of a broader strategy for the managed 
entry of MDs, involving decisions about (i) which MDs should be prioritized for further 
research (ii) the design of the clinical and economic evaluations and (ii) the 
arrangements for pricing and reimbursement of the device, both while under further 
study and after the results of the subsequent clinical and economic evaluation 
become available. (This is discussed further in Section 3 below.) 
 
2.2 Improving economic evaluation methods 
 
Two recent systematic reviews shed some light on the current status of the economic 
evaluation of devices. Ciani et al (2017) analysed a sample of HTA reports in the 
cardiovascular field in order to assess whether there were any key differences in the 
methods employed in studies of MDs, as compared with studies of pharmaceuticals. 
They found that there were several differences: (i) in the types of clinical studies 
forming the basis of the HTAs (with a greater reliance on observational studies, and 
less reliance on RCTs in the case of MDs); (ii) how the health problem and use of the 
technology were considered; (iii) the description and technical characteristics of the 
technology and; (iv) the consideration of the organizational aspects of use of the 
technology. Most of these differences arose because of the relative complexities in 
the use of devices, in terms of the number of interacting components, such as the 
number of groups and organizational levels targeted by the intervention, the number 
and variability of the outcomes and the degree of flexibility or tailoring of the 
intervention. 
 
In the second review, Tarricone et al (2017b) reviewed all the published economic 
evaluations and HTA reports for two cardiac devices, TAVI (an example of an 
emerging technology) and implantable cardioverter defibrillators (an example of a 
mature technology). The authors assessed each study using the CHEERS 
(Consolidated Health Economic Evaluation Reporting Standards) checklist 
(Husereau et al 2014), supplemented by some additional categories reflecting the 
special characteristics of MDs. In general, the methods used in the studies were 
fairly representative of the broader economic evaluation literature. However, the 
special characteristics of MDs were not very well addressed. A learning curve was 
considered in only 16% of studies on TAVI. Incremental innovation was more 
frequently mentioned in the studies of ICDs, but its impact was considered in only 
34% of the cases. Dynamic pricing was the most recognized feature, but was 
empirically tested in less than half of studies of TAVI and only 32% of studies on 
ICDs. Finally, organizational impact was considered in only one study of ICDs but in 
almost all studies on TAVI, but none of the studies of estimated the size of any 
impact. 
 
2.2.1 Improving the analysis of the available clinical data 
 
If the methods of economic evaluation of MDs are to be improved, progress needs to 
be made in compensating for the paucity of well-controlled clinical studies of devices 
and in addressing the special characteristics of MDs. There is much to do in both 
these areas, but several examples of good practice can be identified. First, in a 
recent study of total hip replacement, Schnell-Inderst et al (2017) used a method of 
(clinical) evidence synthesis that allows for the meta-analysis of RCT and 
observational data, using bias adjustment based on formal elicitation. They 
performed an elicitation exercise using methodological and clinical experts to 
determine the strength of beliefs about the magnitude of internal and external bias 
affecting estimates of treatment effect. They incorporated the bias-adjusted treatment 
effects into a generalized evidence synthesis, using both frequentist and Bayesian 
statistical models, calculating relative risks as summary effect estimates with 95% 
confidence/credibility intervals to capture uncertainty. They found that the pooled 
effect size strongly depended on the inclusion of observational data as well the use 
bias-adjusted estimates. The use of the bias-adjusted estimates shifted the pooled 
effect towards a lower treatment effect. 
 
There still remains the challenge of producing unbiased estimates of treatment effect 
when only observational studies are available. In the economic evaluation more 
generally, either propensity scoring, a form of matching, and multivariate regression 
are frequently used. The methods either consider known confounders only, or also 
unknown confounders through the use of instrumental variables in the multivariate 
regression (Prentice JC et al 2014). Examples of the use of observational data to 
assess the cost-effectiveness of MDs include the study by Armeni et al (2016) on 
MitraClip for patients with moderate/severe mitral regurgitation and by Rognoni et al 
(2016) on transarterial radioembolization for patients with hepatocellular carcinoma. 
Both of these studies used the propensity scoring method. 
 
A detailed discussion of the methodological considerations in using propensity 
scoring or multivariate regression to adjust for potential biases in observational 
studies is beyond the scope of this paper. However, it is worth noting that all these 
methods require data on the clinical characteristics of patients, for incorporation in 
the statistical model. These data may not always be available from administrative 
databases, or even some clinical registries. In addition, there may be unobserved 
factors that lead to bias in observational studies. In principle, the use of an 
instrumental variable can be useful, but the challenge is often to find a suitable 
instrument. 
 
As was mentioned earlier, the most common clinical studies of MDs are clinical 
registries, conducted either in the pre-market or post-market phase. However, the 
vast majority of these registries study only a single device, or have very little 
information on factors that might be used as covariates in a multivariate analysis. 
Therefore is an urgent need is to improve the quality of registries for MDs, by making 
sure that there is treatment variation (eg including more than one device), classifying 
the risk categories of patients and, where possible, capturing data on resource use 
and the quality of life of patients (Tarricone et al, 2017c) 
 2.2.2. Estimating the learning curve 
 
As was mentioned earlier, the learning curve for the use of some devices has been 
estimated, either within the context of a clinical trial, or by using an observational 
dataset, such as an administrative database. In the context of an economic 
evaluation of a new MD, an analyst can either use an estimate of the learning 
obtained for a similar device, or attempt to estimate the learning curve as part of the 
economic evaluation. An example of the first approach is the study by Varabyova et 
al (2017) cited earlier. The main issue in this case is whether previous estimates are 
good predictors of the likely learning curve for the new device. To this end it may be 
possible to group MDs in various categories, according to whether they are likely to 
have a shallow or a steep learning curve.  
 
The learning curve has almost never been estimated as part of an economic 
evaluation. In the review by Tarricone et al (2017b), the learning curve was 
addressed in 16% of the studies on TAVI by varying the rates of complications and 
procedure success in a sensitivity analysis. Although there has been an extensive 
review of the impact of learning curves on outcomes (Ramsay et al, 2001), there 
have been very few assessments on the impact of learning curves on resource use 
or costs. See van Gestel et al (2013), Bell et al (2015) and Margier et al (2015) for 
recent examples. 
 
2.2.3 Considering incremental innovation 
 
Two issues are raised by incremental innovation. First, if the MD under study 
changes, this change may be substantial enough to render the previous clinical data 
out of date. This issue arises when product modifications are submitted to the 
regulatory bodies for approval. One analysis in the US showed that for 77 original 
market authorization applications for cardiac implantable electronic devices since 
WKH)'$KDVDSSURYHGµVXSSOHPHQWV¶UHIOHFWLQJSURGXFWPRGLILFDWLRQV,Q
the vast majority of cases the FDA deemed that new clinical data were not 
necessDU\DOWKRXJKRIWKHVXSSOHPHQWVUHODWHGWRFKDQJHVLQWKHGHYLFH¶V
design (Rome et al, 2014). 
 
At the very minimum, analysts should note any product modifications that have 
occurred to the version of the device for which clinical data are available and 
comment on whether these are likely to impact on device performance. It may be 
concluded that many of the modifications are quite minor and likely only to impact of 
convenience of use, such as miniaturisation of the device. Others, such as an 
increase in battery life, may reduce costs if they reduce the need for replacing an 
implantable device. The impact of other modifications, such a change in the design of 
the device, could affect performance positively or negatively. Therefore data 
collection should be put in place to estimate any change, particularly if the design 
change is likely to mean that users face a new learning curve.  
 
The other issue raised by incremental innovation is that the benefits to patients of a 
small change in the deign of an MD may not be detectable by generic preference-
based quality of life measures, like the EQ-5D, that are used to estimate the QALYs 
gained by a new therapy. Therefore, some analysts have used EHVSRNHµXWLOLW\¶
measures, willingness-to-pay estimates or discrete choice experiments in order to 
assess the various attributes of MDs. For example, Chancellor et al (2008) used 
bespoke utility scenarios to assess the benefits of inhaled insulin (using a device) as 
compared with injected insulin. They found a marginal increase in utility owing to the 
greater convenience offered by the inhaler.   
 In a systematic review of willingness-to-pay studies and discrete choice experiments 
of devices, Wilkinson and Drummond (2015) found 30 relevant empirical studies, 
covering technologies such as hearing aids, insulin delivery systems, Cochlear 
implants and endoscopy. They found that, in addition to clinical effectiveness, the 
studies assessed the value of attributes such as convenience/ease of use, length 
and/or frequency of treatment, visibility/size and method of treatment delivery.  
 
These studies are useful in exploring which attributes of treatment are valued by 
patients and the trade-offs they make among the various attributes, but their use in 
resource allocation decisions is uncertain. Some health care decision-makers may 
not feel it appropriate to pay extra for benefits like increased convenience, unless this 
leads to an increase in treatment adherence and hence outcome. Also, many 
decision-makers value the standardization in methods offered by the generic 
preference-based measures, even if they fail to reflect some of the benefits of 
therapies. 
 
2.2.4 Assessing organizational impact 
 
As mentioned earlier, the potential for organizational impact is often mentioned in 
economic evaluations of MDs, but almost never explored quantitatively. Therefore, it 
is important that economic evaluations of MDs consider a wide range of costs; 
specifically, the costs of the infrastructure necessary to accommodate the device (eg 
catheter laboratories of hybrid operating rooms, the cost of training in the use of the 
new device and the creation of multidisciplinary teams). In addition, any impact of the  
new device on procedure costs should be quantified, by measuring any increase in 
the volume in procedures, or the conversion of procedures from an inpatient to an 
outpatient setting. 
  
2.2.5 Accounting for dynamic pricing 
 
Economic evaluations of MDs should anticipate future price changes by conducting a 
sensitivity analysis of device acquisition cost, or by identifying the threshold price at 
which the device is no longer cost-effective. For example, in the NICE re-appraisal of 
drug-eluting stents mentioned above (NICE, 2003), it was determined that DES 
would be cost-effective unless the price was more than £300 higher than the price of 
bare metal stents. 
 
 
3. Managing the diffusion of MDs 
 
Understanding the factors that lead to the adoption of MDs is especially important to 
health care decision makers because the regulatory barriers to market access are 
considerably lower for MDs than for pharmaceuticals. A number of studies have 
shown that the utilization of MDs varies substantially, both within and between 
countries (Valzania et al, 2015). In a recent study, Torbica et al (2017) used a panel 
data regression model to investigate the variation in implant rates for cardiac 
implantable electrical devices across 57 regions in 5EU countries. By analysing a 
total of 1,330,098 hospitalizations extracted from discharge databases in Austria, 
England, Germany, Italy and Slovenia from 2008 to 2012, they found implant rates 
were positively associated with higher levels of tertiary education among the labour 
force and the percentage of population over 74 years old. Regional per capita GDP 
and the number of implanting centres appeared to have no significant effect. There 
were also significant country effects in some of the analyses, suggesting that 
institutional factors play a role. 
 In another recent study, Hatz et al (2017) investigated the characteristics of 
organizations (ie hospitals) and individuals (ie clinicians) that are more inclined to 
adopt and utilize cardiovascular devices based on a comprehensive analysis of 
environmental, organizational, individual and technological factors. Seven random 
intercept hurdle models were estimated using data obtained from 1249 surveys 
completed by members of the European Society of Cardiology. They found that 
better (device) manufacturer support increased the adoption probability of new 
cardiac devices (defined by CE mark approval dates) and that budget pressure 
increased the adoption probability of older devices. They argue that the role of 
manufacturer support should be investigated in more detail in order to assess 
whether it functions as a substitute for medical evidence on new devices and to gain 
insights about its relationship with clinical and cost-effectiveness. 
 
This goes to the heart of the matter. Namely, if wide variation is observed in the 
utilization of MDs across countries and regions, is the level of utilization in each 
jurisdiction µDSSURSULDWH¶defined in terms of clinical and cost-effectiveness), or are 
devices being overused in some jurisdictions and inappropriately restricted in others? 
Ideally one would investigate the link between the use of the technologies and the 
patient outcomes obtained, but this is not possible using routinely available data. 
$OWHUQDWLYHO\LWPD\EHSRVVLEOHWRLQYHVWLJDWHZKHWKHUSK\VLFLDQV¶SUDFWLFHVDUHLQ
line with accepted clinical guidelines, although with a few notable exceptions (eg 
1,&(¶VFOLQLFDOJXLGHOLQHVLQWKH8.ZZZQLFHRUJXNWKHVHGRQRWFRQVLGHUFRVW-
effectiveness.  
 
Another approach would be to use economic evaluation to manage the diffusion of 
MDs, by conducting studies not only at market entry, but also in the post-market 
phase. In recent years there has been a growth in managed entry agreements that 
are collectively known as performance-based risk-sharing arrangements (PBRSAs). 
These schemes are known by different names, and take slightly different forms, in 
GLIIHUHQWMXULVGLFWLRQVVXFKDVµFRYHUDJHZLWKHYLGHQFHGHYHORSPHQW¶LQWKH86µILHOG
HYDOXDWLRQV¶LQ&DQDGDRUµRQO\ZLWKUHVHDUFK¶LQWKH8.7KHEDVLFDSSURach is that 
new technologies are reimbursed by the health care system on the condition that 
further research is conducted into the clinical and/or cost-effectiveness of the 
technology. This approach is particularly well-suited to MDs, since they are less well 
studied in clinical trials in the pre-market phase and that, because of the potential for 
a learning curve and incremental innovation, it is likely that clinical and cost-
effectiveness in regular clinical practice will differ substantially from that observed in 
an experimental setting such as a controlled clinical trial. 
 
Garrison et al (2013) reviewed PBRSAs existing in a number of countries. Under 
their working definition, a PBRSA exhibits the following key characteristics (i) there is 
a programme of data collection agreed between the manufacturer and the payer (ii) 
the data collection is typically initiated during the time period following regulatory 
approval (iii) the price, reimbursement and/or revenue for the product are linked to 
the outcome of the programme of data collection (iv) the data collection is intended to 
address uncertainty (eg the uncertainty could be about the efficacy or effectiveness 
in the treatment population tested in the pre-market phase, the efficacy or 
effectiveness in a broader population or in the long term, adverse events or 
DGKHUHQFHLVVXHVZKHWKHUKHDOWKFDUHSURYLGHUV¶DFWXDOPDQDJHPHQW of patients 
affects outcomes, the size and value of cost offsets, the number and attributes of the 
patients treated in practice) and (v) the arrangements provide a different distribution 
of risk between the payer and manufacturer than under the normal reimbursement 
arrangements.  
 
Examples of PBRSA for procedures involving devices initiated in the US include 
those for positron emission tomography for cancer diagnosis, percutaneous 
transluminal angioplasty and stenting for secondary prevention of stroke and spinal 
cord stimulation for failed back surgery syndrome (Garrison et al, 2013). In another 
example of a PBRSA in Ontario (Canada), the generalizability of existing randomised 
controlled trials of drug-eluting stents (DES), which had been conducted in the US, 
was questioned. Therefore, a pragmatic registry of all patients receiving DES was 
HVWDEOLVKHGLQRUGHUWRFRQGXFWDµILHOGHYDOXDWLRQ¶Coverage was provided for the 
stents provided under the registry. It was found that DES was more effective only in 
patients at high risk of stenosis (eg those with diabetes, or particularly long or narrow 
lesions). Since this represented about 30% of the whole patient population, it was 
argued that this policy saved between $35-58 million, as compared with the potential 
uncontrolled adoption of DES (Levin et al, 2007; Goeree et al, 2009). 
 
The key questions in using economic evaluation to manage the diffusion of MDs 
concern the timing of studies (eg before or after providing reimbursement) and the 
nature of the research (eg the parameters estimated and the methods used). Making 
a device available early can have benefits, as it allows patient access to potentially 
beneficial therapies. However, decisions about the use of the device when the 
evidence base is relatively immature can lead to clinical and financial risk. Also, once 
the device is generally available, the possibilities for further research to reduce 
uncertainty may be limited, either because manufacturers have fewer incentives to 
invest in further research, or because patients and clinicians are unwilling to 
participate in studies, especially RCTs. 
 
Health economists have explored the use of value of information analysis to 
determine the balance between the benefits of early access to a technology and the 
value of additional evidence to resolve uncertainty (Claxton et al, 2012). In a recent 
paper, Rothery et al (2017) set out a framework for considering the issues relating to 
the uncertainty in the diffusion and use of MDs, considering the learning curve, 
incremental innovation, investment and irrecoverable costs and dynamic pricing. 
They use this framework to illustrate the circumstances under which it might be 
preferable to restrict access to the device until further research establishes its value, 
or preferable to allow access as long as further research is conducted. 
 
Rothery et al (2017) also discuss the incentives for further research and how the 
value and cost of such research might be shared between the manufacturer and the 
health care sector. Drummond et al (2016) argue that incentives to manufacturers to 
conduct research need particular attention, give the lack of data exclusively 
mentioned earlier. In a situation where a PBRSA has been established for the first 
device to market, this might provide an opportunity for different manufacturers to 
share the costs of the research, as opposed to most of the costs being borne by the 
ILUVWWRPDUNHW)RUH[DPSOHµIDVWIROORZHU¶GHYLFHVFODLPLQJVXEVWDQWLDOHTXLYDOHQFH
could be included in the scheme, thereby sharing the costs of the research and 
generating evidence on the comparative effectiveness of the different devices. 
 
 
4. Concluding remarks 
 
In this paper we have outlined the key challenges in conducting economic 
evaluations of MDs and how they might be tackled. However, many methodological 
and policy challenges remain and further research is required. First, approaches 
need to be developed to integrate regulatory and health technology assessment for 
MDs, so that future data needs can be anticipated when clinical studies are being 
planned. It is likely that the balance of data collection for the economic evaluation of 
MDs will be in the post-marketing phase. Therefore, effort needs to be placed of the 
DQDO\VLVRIµUHDO-ZRUOG¶costs and effects of devices in regular clinical use. Linked to 
this, attention needs to given to the design of clinical registries, so that these will also 
be useful for conducting economic evaluations, as well as establishing the efficacy 
and safety of MDs. 
 
Secondly, more study is required to explore the impact of the various distinctive 
characteristics of medical devices. In particular, it would also be useful to determine 
whether it is possible categorize devices in terms of their likely learning curve, 
according to the types of technology (diagnostic or therapeutic; implantable or non-
implantable), the medical specialty, or device risk class. In additional, there should be 
more quantitative assessments of the organizational impact of MDs 
 
Finally, further study is required of the various influences on the diffusion of devices, 
especially the motivational factors facing patients, clinicians and the institutions in 
which they work. In turn this could help improve the design and conduct of PBRSAs, 
which are likely to be central to the economic evaluation of MDs in the future. 
 
Further reading 
 
(a) The specific characteristics of MDs: the following two papers discuss the 
arguments for and against considering the specific characteristics of medical devices 
when conducting economic evaluations. 
 
Drummond, M.F., Griffin, A., Tarricone, R. (2009) Economic evaluation for devices and 
drugs. Same or different? Value in Health; 12(4): 402-404. 
 
(b) The need to strengthen the regulation of MDs: this paper discusses this issue in the 
context of the US and Europe. 
 
Sorenson, C., Drummond, M.F. (2014). Improving medical device regulation: the US 
and Europe in perspective. The Milbank Quarterly; 92:1, 114-150. Doi: 
10.1111/1468-0009.12043.  
 
(c) Challenges in the assessment of medical devices:this journal supplement 
describes the results of the European Union MedtecHTA Project, a recent and 
comprehensive research effort in the economic evaluation of MDs. 
 
Tarricone, R, Torbica, A, Drummond, MF, Schreyögg J. (2017). Assessment of 
medical devices: challenges and solutions. Health Economics; 26(Suppl. 1): 1-152. 
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